Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05489679 | A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer | terminated | Phase 1 | 6 | Accutar Biotechnology IncINDUSTRY | 1 | Jan 25, 2024 | clinicaltrials |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | terminated | Phase 1 | 16 | Kite, A Gilead CompanyINDUSTRY | 1 | Jan 24, 2024 | clinicaltrials |
| NCT03422679 |
| Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies |
| terminated |
| Phase 1 / Phase 2 |
| 79 |
| Cellestia Biotech AGINDUSTRY |
| 6 |
| Jan 16, 2024 |
| clinicaltrials |
| NCT03992131 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) | terminated | Phase 1 / Phase 2 | 25 | pharmaand GmbHINDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT03149549 | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 99 | CytomX TherapeuticsINDUSTRY | 4 | Jan 5, 2024 | clinicaltrials |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | terminated | Phase 1 | 87 | Atreca, Inc.INDUSTRY | 1 | Dec 29, 2023 | clinicaltrials |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 6 | Fusion Pharmaceuticals Inc.INDUSTRY | 2 | Dec 19, 2023 | clinicaltrials |
| NCT03861403 | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors | terminated | Phase 1 | 10 | Leap Therapeutics, Inc.INDUSTRY | 1 | Nov 30, 2023 | clinicaltrials |
| NCT03190967 | T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery | terminated | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Oct 11, 2023 | clinicaltrials |
| NCT04139993 | RBX7455 Before Surgery for the Treatment of Operable Breast Cancer | terminated | Phase 1 | 3 | Mayo ClinicOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT05395052 | FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | terminated | Phase 1 | 5 | Fate TherapeuticsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT00934895 | Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca | terminated | Phase 1 / Phase 2 | 27 | Rutgers, The State University of New JerseyOTHER | 1 | Sep 18, 2023 | clinicaltrials |
| NCT04441099 | NBE-002 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 12 | NBE-Therapeutics AGINDUSTRY | 1 | Sep 7, 2023 | clinicaltrials |
| NCT04185311 | Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted | terminated | Phase 1 | 6 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT00765765 | Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 6 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT04639245 | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT03576131 | GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 3 | Aug 1, 2023 | clinicaltrials |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 4 | Jul 25, 2023 | clinicaltrials |
| NCT04541225 | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors | terminated | Phase 1 | 74 | Nuvation Bio Inc.INDUSTRY | 1 | Jul 14, 2023 | clinicaltrials |
| NCT04942054 | A Study in Patients With Advanced Breast Cancer | terminated | Phase 1 | 9 | Sun Pharma Advanced Research Company LimitedINDUSTRY | 2 | May 22, 2023 | clinicaltrials |
| NCT02890368 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides | terminated | Phase 1 | 56 | PfizerINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies(REVEAL) | terminated | Phase 1 / Phase 2 | 64 | Nektar TherapeuticsINDUSTRY | 1 | Mar 8, 2023 | clinicaltrials |
| NCT02834247 | A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors | terminated | Phase 1 | 41 | Calithera Biosciences, IncINDUSTRY | 4 | Feb 8, 2023 | clinicaltrials |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | terminated | Phase 1 / Phase 2 | 201 | Incyte CorporationINDUSTRY | 2 | Jan 6, 2023 | clinicaltrials |
| NCT02474173 | Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer | terminated | Phase 1 | 31 | National Cancer Institute (NCI)NIH | 1 | Nov 4, 2022 | clinicaltrials |
| NCT03579472 | M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer | terminated | Phase 1 | 38 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2022 | clinicaltrials |
| NCT03128619 | Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer | terminated | Phase 1 | 10 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 26, 2022 | clinicaltrials |
| NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | terminated | Phase 1 | 21 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT02457910 | Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 30 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | terminated | Phase 1 | 61 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY | 2 | Aug 18, 2022 | clinicaltrials |
| NCT05091528 | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers | terminated | Phase 1 / Phase 2 | 2 | Silverback TherapeuticsINDUSTRY | 1 | Aug 18, 2022 | clinicaltrials |
| NCT00754312 | A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer | terminated | Phase 1 | 1 | Syndax PharmaceuticalsINDUSTRY | 1 | Jun 6, 2022 | clinicaltrials |
| NCT04178460 | A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment | terminated | Phase 1 | 60 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Jun 1, 2022 | clinicaltrials |
| NCT02824575 | Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer | terminated | Phase 1 | 28 | Montefiore Medical CenterOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT04197999 | A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer | terminated | Phase 1 | 4 | GlycoMimetics IncorporatedINDUSTRY | 1 | Mar 22, 2022 | clinicaltrials |
| NCT02628535 | Safety Study of MGD009 in B7-H3-expressing Tumors | terminated | Phase 1 | 67 | MacroGenicsINDUSTRY | 3 | Feb 8, 2022 | clinicaltrials |
| NCT04296942 | BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT) | terminated | Phase 1 | 1 | National Cancer Institute (NCI)NIH | 1 | Jan 11, 2022 | clinicaltrials |
| NCT02204462 | FBnTP Imaging of Breast Cancer | terminated | Phase 1 | 4 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT04298918 | A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 1 | Hoffmann-La RocheINDUSTRY | 2 | Nov 8, 2021 | clinicaltrials |
| NCT03822715 | NEOBREADS: Neoadjuvant Breast Diet Study(NEOBREADS) | terminated | Phase 1 | 2 | Monica MitaOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | terminated | Phase 1 | 2 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 31, 2021 | clinicaltrials |
| NCT03566485 | Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer | terminated | Phase 1 / Phase 2 | 12 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 11, 2021 | clinicaltrials |
| NCT03982004 | Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer | terminated | Phase 1 | 1 | Washington University School of MedicineOTHER | 1 | Jun 21, 2021 | clinicaltrials |
| NCT01823835 | A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer | terminated | Phase 1 / Phase 2 | 152 | Genentech, Inc.INDUSTRY | 4 | Jun 18, 2021 | clinicaltrials |
| NCT03983395 | Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 1 | Ichnos Sciences SAINDUSTRY | 1 | May 24, 2021 | clinicaltrials |
| NCT02936206 | Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant. | terminated | Phase 1 | 2 | Icahn School of Medicine at Mount SinaiOTHER | 1 | May 19, 2021 | clinicaltrials |
| NCT03134638 | A Study of SY-1365 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 | 107 | Syros PharmaceuticalsINDUSTRY | 3 | Mar 9, 2021 | clinicaltrials |
| NCT03125200 | Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression | terminated | Phase 1 | 21 | ADC Therapeutics S.A.INDUSTRY | 2 | Feb 1, 2021 | clinicaltrials |
| NCT02698176 | A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006) | terminated | Phase 1 | 13 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 27, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Jan 25, 2024source: clinicaltrials